ADVERTISEMENT

In the Literature

The Hospitalist. 2008 November;2008(11):

Literature at a Glance

LMWH after Arthroscopic Knee Surgery May Prevent VTE Compared to Graduated Compression Stockings

Clinical question: Does low molecular weight heparin (LMWH) prevent venous thromboembolism (VTE) compared to compression stockings without increasing bleeding complications in arthroscopic knee surgery?

Background: Knee arthroscopy is a common orthopedic surgery and postoperative venous thromboprophylaxis is not routinely recommended.

Study design: Randomized, controlled trial with blinding of the investigators.

Setting: Single orthopedic clinic in Italy, with followup at a university hospital.

Synopsis: 1,761 consecutive patients undergoing knee arthroscopy were randomly assigned to full-length graduated compression stockings (CS) for seven days postoperatively, subcutaneous LMWH (nadoparin 3800 units daily) for seven or 14 days postoperatively. The primary outcome of asymptomatic proximal deep venous thrombosis (DVT), symptomatic VTE, and all-cause mortality within three months of surgery was higher with CS (3.2%) than with LMWH for seven or 14 days (0.9% in each group) (P=0.005). There was no significant difference in bleeding events between groups.

The study was underpowered to detect differences in bleeding risk. Furthermore, almost half the events making up the primary outcome were distal DVTs of uncertain clinical significance. Notably, the 14-day LMWH group was discontinued early because of unspecified safety concerns related to longer exposure to LMWH.

Bottom line: Postoperative prophylactic LMWH for seven days may prevent some thromboses after knee surgery and should be considered in higher-risk patients.

Citation: Camporese G, Bernardi E, Prandoni P, et al. Low-molecular-weight heparin versus compression stockings for thrombophylaxis after knee arthroscopy. Ann Intern Med. 2008;14(9):73-82.

CLINICAL SHORTS

Post-discharge patient interviews reveal adverse events not evident in the medical record

In a survey of patients and review of the medical records six to 12 months after discharge, 23% of patients and 11% of physicians reported significant adverse events; patients and physicians reported different events (κ=0.20).

Citation: Weissman JS, Schneider ED, Weingart SN et al. Comparing patient-reported hospital adverse events with medical record review: do patients know something that hospitals do not? Ann Intern Med. 2008;149:100-108.

A Peripheral IV can be left in place until replacement is clinically indicated

Randomized, controlled trial showed no difference in catheter failure (phlebitis and infiltration) and significant cost savings when peripheral IVs were replaced for clinical indication rather than scheduled every 72 to 96 hours.

Citation: Webster, J, Clarke, S, Paterson, D, et al. Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial. BMJ. 2008;337:339.

CHADS2 is a good predictor of stroke risk in chronic atrial fibrillation, but may be improved further

Refining the CHADS2 prediction rule from epidemiological data by further stratifying age, adding gender, and recalibrating risk factors, improved the predictive value, but is not as user friendly.

Citation: Rietbrok S, Heeley E, Plumb J, Van Staa T. Chronic atrial fbrillation: Incidence, prevalence, and predication of stroke using the congestive heart failure, hypertension, age>75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57-64.

Consider empiric anti-Pseudomonal coverage in patients with risk factors for Pseudomonas bacteremia

In patients with suspected sepsis, a retrospective cohort study of 614 patients identified neutropenia, septic shock, indwelling central venous catheter, and health-care-associated status as independent predictors for P. aeruginosa bacteremia.

Citation: Cheong HS, Kang CI, Wi YM, et al. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. Am J Med. 2008;121(8):709-714.

Empiric fluconazole does not improve clinical outcomes in ICU patients

Multi-center, randomized, controlled trial of 270 ICU patients at high-risk for invasive candidiasis given empiric fluconazole 800 mg daily versus placebo did not demonstrate improved outcome, such as fever resolution (RR 0.95).

Citation: Schuster M, Edwards J, Sobel J, et al. Empirical fluconazole versus placebo for intensive care unit patients. Ann Int Med. 2008;149:83-90.

Combination endoscopic and beta-blocker therapy reduced variceal rebleeding in cirrhosis compared to either therapy alone

In patients admitted with variceal bleeding, meta-analysis of 23 randomized trials found combined endoscopic and beta-blocker therapy reduced rebleeding rates by about one-third compared with either therapy alone, but mortality was not reduced.

Citation: Gonzalez R, Zamora J, Gomez-Camerero J, Molinero LM, Bañares R, Albillos A. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149:109-122.